Retatrutide 30mg

Description

Retatrutide is an investigational triple receptor agonist simultaneously targeting GIP, GLP-1, and glucagon receptors — a mechanism that has positioned it as one of the most comprehensively characterized next-generation metabolic peptides in clinical research.

Research Overview

Phase 2 data published in The New England Journal of Medicine (2023) demonstrated mean weight reductions of 17.5% at 24 weeks and up to 24.2% at 48 weeks — among the largest reductions observed in any pharmacological intervention studied to date. The triple-agonist mechanism has been studied for its additive contributions: GLP-1 receptor activation drives satiety and slowed gastric emptying; GIP agonism potentiates insulin response and modulates adipose tissue; glucagon receptor activation increases thermogenesis and hepatic fat mobilization. Mechanistic research has examined the relative receptor activation ratios and their differential contributions to weight loss, lipid metabolism, and glycemic control. Phase 1 data established a tolerability and pharmacokinetic profile across dose escalation cohorts. Ongoing Phase 3 trials are examining effects in type 2 diabetes (TRIUMPH program) and non-alcoholic steatohepatitis, with metabolic biomarker data continuing to expand the characterization of triple incretin receptor co-activation. Teams building on the Phase 2 dataset have noted particular interest in the glucagon component’s role in thermogenesis — an area of active mechanistic investigation.

Key References

• Jastreboff AM et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.
• Frías JP et al. (2023). Retatrutide for Type 2 Diabetes: a Randomized Phase 2 Trial. The Lancet.
• Coskun T et al. Mechanistic characterization of LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist. Molecular Metabolism. [PubMed Search]